Riskpilot← Back to searchSign inGet full accessPharmaRelations AB
ABActiveOrg 5565447983Frösundaviks Allé 1 6trBusiness and other management consultancy activities · NACE 7020Est. 1997136 employees
Revenue 2024
SEK 226,6M
-10% vs 2023
EBITDA margin
4.5%
-47% vs 2023
Equity ratio
50.5%
Financial strength
Net profit 2024
SEK 6,8M
-43% vs 2023
| Revenue | SEK 226,6M | -10% |
| EBITDA | SEK 10,1M | -47% |
| Net profit | SEK 6,8M | -43% |
| Total assets | SEK 91,5M | -2% |
| Equity | SEK 46,2M | +17% |
| Employees | 136 | — |
Legal name
PharmaRelations AB
Org number
5565447983
Legal form
Aktiebolag
NACE code
7020 · Business and other management consultancy activities
Founded
12 augusti 1997
Share capital
SEK 106 000
Employees
136 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget skall bedriva konsultverksamhet inom läkemedelsbranschen med inriktning mot försäljning och marknadsföring.
Address
Frösundaviks Allé 1 6tr
Phone
+46859074580
Email
yvonne.hedlund@pharmarelations.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 113 015 | 148 633 | 223 109 | 251 081 | 226 647 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 12 638 | 13 690 | 18 984 | 19 025 | 10 132 |
| Depreciation & amort. | −49 | −103 | −103 | −73 | −73 |
| EBIT | 12 589 | 13 587 | 18 881 | 18 952 | 10 059 |
| Net financials | −313 | −104 | −321 | 363 | 769 |
| Profit before tax | 12 214 | 10 513 | 15 515 | 15 275 | 8 878 |
| Tax | −2 721 | −2 253 | −3 425 | −3 306 | −2 053 |
| Net profit | 9 493 | 8 260 | 12 090 | 11 969 | 6 825 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 39 542 | 54 861 | 72 783 | 93 445 | 91 459 |
| Equity | 16 805 | 15 065 | 27 387 | 39 356 | 46 180 |
| Long-term debt | 82 | 6 082 | 4 587 | 86 | 86 |
| Short-term debt | 14 515 | 22 574 | 26 410 | 35 303 | 24 293 |
| Total debt | 14 597 | 28 656 | 30 997 | 35 389 | 24 379 |
EBITDA margin
4.5%
This company
15.8%
Market median
-72% vs market
20202024
Equity ratio
50.5%
This company
38.2%
Market median
+32% vs market
20202024
Return on equity
14.8%
This company
18.4%
Market median
+20% vs market
20202024
Net profit margin
3.0%
This company
8.1%
Market median
-63% vs market
20202024
Asset turnover
2.48×
This company
1.12×
Market median
+121% vs market
20202024
Debt / equity
0.98×
This company
0.62×
Market median
+58% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
ÅM Chief Executive Officer | Chief Executive Officer | 2024 |
CF Audit | Audit | 2022 |
| Former (1) | ||
FG Chief Executive Officer | Chief Executive Officer | 2022 – 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Hofsberger Development ABPharma & Health Relations AB
PharmaRelations AB (this company)Pharmarelations OyPHARMARELATIONS ASPharmarelations ApsPharmarelations ASPHARMARELATIONS APSPHARMARELATIONS OYBoard members of PharmaRelations AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Åsa Maria Uppströmer | Chief Executive Officer | 0 companies |
| Carl Fredrik Niring | Audit | 0 companies |
| Fredrik Gunnar Åke Anjou | Chief Executive Officer | 0 companies |
| Carl Magnus Olof F O Hofsberger | Deputy Board Member | 0 companies |
| Lena Birgitta Andersson Hofsberger | Board of Directors | 0 companies |